Gary Yeoman
Internal Medicine · Philadelphia, PANPI 1962430314
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.2%), travel and lodging and education — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 57.9% of the total. Reporting peaked in 2024 at $2,631 and has fallen 99.3% since, to $17 in 2025. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $34.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$3K
- Amgen$326
- Novo Nordisk$259
- AbbVie$190
- Amarin Pharma, Inc.$170
- Pfizer$134
- plus $837 from 20 others
Across 880 payments — averaging $2751.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$864K
- AbbVie$672K
- AstraZeneca$217K
- Boehringer Ingelheim$194K
- Hoffmann-la Roche Limited$163K
- Amgen$126K
- plus $186K from 7 others
What the payments were for
- Travel & lodging$2,25150%
- Food & beverage$2,28250%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 11 | $2,631 |
| Amgen | 17 | $326 |
| Novo Nordisk | 15 | $259 |
| AbbVie | 16 | $190 |
| Amarin Pharma, Inc. | 12 | $170 |
| Pfizer | 9 | $134 |
| AstraZeneca | 8 | $105 |
| Merck | 6 | $95 |
| Johnson & Johnson(2 entities) | 5 | $91 |
| Lilly USA, LLC | 5 | $72 |
| Astellas Pharma US Inc | 4 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $57 |
| Nestle Healthcare Nutrition Inc. | 3 | $57 |
| Bayer | 3 | $50 |
| Vertos Medical, Inc. | 1 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $30 |
| Boehringer Ingelheim | 2 | $27 |
| Abbott | 2 | $27 |
| Gilead | 2 | $26 |
| Orexo US, Inc. | 1 | $24 |
| Exact Sciences | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| GSK | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Novartis | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$4,547 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 11 | $207 |
| Atorvastatin Calcium | 14 | $127 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Philadelphia
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- David GoldmannPhiladelphia$525K
- Eyob FeyssaPhiladelphia$328K
- Emil AbramianPhiladelphia$199K
- Michael KnightPhiladelphia$178K
- James BlakePhiladelphia$164K
- Gina SimonciniPhiladelphia$158K
- James LewisPhiladelphia$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.